ADVR to Present at Rodman & Renshaw Global Healthcare Conference; 2nd Annual Global Healthcare Conference to be held from May 4th-May 5th, 2005.

YONKERS, N.Y. -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) announced today that its President and CEO, Dr. Elma Hawkins, will present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference on Wednesday, May 4, 2005 in Paris, France.

"We are extremely pleased to be presenting at the Rodman & Renshaw Global Healthcare Conference," said Dr. Hawkins. "This is a well-known, premier healthcare conference, and it will give us the chance to speak to many European and U.S. investors."

The presentation will take place at The Intercontinental Hotel in Paris at 10:30 a.m., (local Paris time). It will be simultaneously web cast at 4:30 a.m. EST and archived for 90 days at the following web address: http://www.wsw.com/webcast/rrshq5/advr

About Rodman & Renshaw, LLC:

Rodman & Renshaw, LLC is a privately held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. During the last two years Rodman & Renshaw completed over 60 financing transactions, totaling over $1 billion. Rodman & Renshaw concentrates on emerging growth companies in the life science and technology sectors.

About Advanced Viral Research Corp.:

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com.

ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid complex, which to date has demonstrated a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as those which occur in patients with rheumatoid arthritis.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.